Blood-based biomarkers predicting response to antidepressants

Area of Science:

• Neuroscience
• Psychiatry
• Genetics

Background:

• Major depressive disorder affects 350 million globally, with over 50% not responding to initial antidepressant treatment.
• Current treatment selection relies on clinical judgment, lacking objective, lab-derived measures.
• Biomarkers are emerging as tools to enhance diagnostic accuracy and treatment strategies.

Purpose of the Study:

• To review genetic and blood-based biomarkers for major depressive disorder (MDD).
• To explore biomarkers related to monoamine, inflammatory, and hypothalamic-pituitary-adrenal (HPA) pathways.
• To assess the potential of biomarkers in guiding personalized treatment selection.

Main Methods:

• Review of studies on genetic markers and blood-based biomarkers.
• Analysis of biomarkers within monoamine, inflammatory, and HPA axis pathways.
• Evaluation of evidence for biomarker-guided treatment selection.

Main Results:

• Inflammatory markers and immune cells may predict response to anti-inflammatory treatments.
• HPA axis normalization and neurotrophic factors can indicate stable treatment response.
• Genetic markers in the serotonergic system show potential for identifying vulnerability but lack consistent treatment guidance.

Conclusions:

• Biomarkers, particularly inflammatory and HPA axis markers, show potential for predicting treatment response in major depressive disorder.
• Further research and validation are crucial for integrating biomarkers into clinical practice.
• Biomarker-driven personalized medicine can shorten time to remission for MDD patients.